奇格利塔扎尔在2型糖尿病中具有个性化的降血糖效果
Qi Huang1, Xiantong Zou1, Yingli Chen1
1Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
iScience
|November 9, 2023
概括
奇格利塔扎尔在许多2型糖尿病患者中提供了更好的血糖控制,与西塔格利普丁相比. 一个机器学习模型,ML-PANPPAR,识别了那些最有可能从chiglitazar中受益的人,以进行个性化治疗.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 奇格利塔扎尔是一种PPAR泛激动剂,在2型糖尿病中表现出可比性降血糖效应,与西塔格利在2型糖尿病中表现得相似.
- 确定从特定糖尿病药物中获益最多的患者子组对于个性化治疗至关重要.
研究的目的:
- 通过使用奇格利塔萨与西塔格利普丁,识别具有优越血糖控制的患者子组.
- 开发和验证一种机器学习模型,用于预测智利塔扎尔响应者.
主要方法:
- 两项随机对照试验的后期分析,涉及1,069名2型糖尿病患者.
- 开发一种机器学习模型 (ML-PANPPAR),使用13个基线变量来预测治疗反应.
- 现象映射方法根据治疗疗效划分患者子组.
主要成果:
- 在63.3%的患者中,与西塔利普丁 (p<0.001) 相比,奇格利塔撒对HbA1c的降低更大 (p<0.001).
- 使用性别,BMI,HbA1c,HDL和禁食胰岛素的ML-PANPPAR模型显示出强大的预测性能.
- 现象测绘成功识别了奇格利塔萨尔反应者,从而实现了个性化药物分配.
结论:
- 奇格利塔扎尔在2型糖尿病患者的重要亚组中提供了卓越的血糖控制.
- 通过确定最佳药物选择,ML-PANPPAR模型促进了个性化治疗策略.
- 这种方法支持精准医学在管理2型糖尿病.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Oral Hypoglycemic Agents: Glinides
159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K


